Selective Non-toxics Inhibitors Targeting DHFR for Tuberculosis and Cancer Therapy: Pharmacophore Generation and Molecular Dynamics Simulation
Dihydrofolate reductase (DHFR) is a crucial enzyme that catalyzes the conversion of folic acid. Its reserved properties and significance in both human (h-DHFR) and mycobacterium (mt-DHFR) make it a challenging target for developing drugs against cancer and bacterial infections. Although methotrexate...
Main Authors: | Ghyzlane EL Haddoumi, Mariam Mansouri, Houda Bendani, Mohammed Walid Chemao-Elfihri, Jouhaina Kourou, Hanane Abbou, Lahcen Belyamani, Ilham Kandoussi, Azeddine Ibrahimi |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2023-05-01
|
Series: | Bioinformatics and Biology Insights |
Online Access: | https://doi.org/10.1177/11779322231171778 |
Similar Items
-
In Silico Analyses of All STAT3 Missense Variants Leading to Explore Divergent AD-HIES Clinical Phenotypes
by: Mariam Mansouri, et al.
Published: (2023-04-01) -
Facing Antitubercular Resistance: Identification of Potential Direct Inhibitors Targeting InhA Enzyme and Generation of 3D-pharmacophore Model by in silico Approach
by: EL Haddoumi G, et al.
Published: (2023-04-01) -
A Comprehensive Analysis of 3 Moroccan Genomes Revealed Contributions From Both African and European Ancestries
by: Nasma Boumajdi, et al.
Published: (2024-02-01) -
Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations.
by: Meriem Laamarti, et al.
Published: (2020-01-01) -
Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes: Moving Toward a Universal Vaccine for the “Confined Virus”?
by: Tarek Alouane, et al.
Published: (2020-10-01)